LSE - Delayed Quote USD

(0ADR.L)

244.92

-24.59

(-9.12%)

At close: March 14 at 1:34:29 PM GMT

Insulet Appoints Ashley McEvoy President and CEO

ACTON, Mass., April 28, 2025--Insulet Appoints Ashley McEvoy President and CEO

Business Wire 3 days ago

PODD
Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Simply Wall St. 7 days ago

PODD
This Insulin Pump Maker Expands Into New Territory And Its Stock Shows Relative Strength

This medical device stock is in a base and its relative strength line hit a 52-week high. Insulet's insulin pump is now available in Canada.

Investor's Business Daily 23 days ago

PODD
Insulet (NasdaqGS:PODD) Launches Omnipod 5 In Canada As Shares Dip 7%

Insulet (NasdaqGS:PODD) recently launched the Omnipod 5 system in Canada, marking a noteworthy advancement in diabetes management with public reimbursement already underway in some provinces. Despite this development, the stock dropped 2.6% over the last month. The decline occurred amid broad market volatility, with the Dow Jones and S&P 500 facing sharp losses due to tariff uncertainties and economic recession fears. Additionally, the company's issuance of senior notes and the departure of...

Simply Wall St. 23 days ago

PODD
Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5 is now commercially available in Canada. Omnipod 5 is the first tubeless, waterproof* Automated Insulin Delivery (AID) System approved for use in Canada for people with type 1 diabetes ages two years and above.

CNW Group 24 days ago

PODD
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

ACTON, Mass., April 03, 2025--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

Business Wire 28 days ago

PODD
Insulet Gains 62.9% in a Year: What's Driving the Stock?

PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.

Zacks last month

PODD
Insulet (NasdaqGS:PODD) Completes US$450 Million Debt Financing; 7 Day Share Price Up 5%

Insulet (NasdaqGS:PODD) experienced a 5% increase in share price over the past week, a period marked by significant financial advancements and product developments. The company's successful closure of $450 million in 6.50% Senior Notes and the amendment of its Credit Agreement to increase revolving commitments to $500 million likely bolstered investor confidence. The announcement of new clinical data revealing improvements in HbA1c levels through the Omnipod 5 AID System further positioned...

Simply Wall St. last month

PODD
PODD Stock Gains Following the Launch of Omnipod 5 in Australia

Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

Zacks last month

PODD

MASI

BSX
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

StockStory last month

PODD

DXCM

IRTC
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5

Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.

Zacks last month

PODD

CAH

BSX
LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day

LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day.

Zacks last month

TREE

PODD

MDT
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

MedTech Dive last month

PODD

TNDM
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections

ACTON, Mass., March 19, 2025--Insulet's RADIANT trial demonstrates meaningful glycemic improvements with Omnipod 5 AID following direct transition from multiple daily injections

Business Wire last month

PODD
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan

Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions.

Zacks last month

PODD

MDT

SYK
Insulet Announces Pricing of Senior Notes Due 2033

ACTON, Mass., March 18, 2025--Insulet Announces Pricing of Senior Notes Due 2033

Business Wire last month

PODD
Insulet Corporation (PODD): Among the Best Diabetes Stocks to Buy According to Billionaires

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where Insulet Corporation (NASDAQ:PODD) stands against other best diabetes stocks to buy according to billionaires. The Growing Market and Innovation in Continuous Glucose Monitoring (CGM) Technology The WHO estimates […]

Insider Monkey last month

PODD

GLDAF
Insulet Chief Technology Officer Mark Field leaves

Amit Guliani, group vice president of software engineering, was named acting chief technology officer, effective immediately.

MedTech Dive last month

PODD
Insulet Expands Omnipod® 5 to Four More International Markets

ACTON, Mass., March 18, 2025--Insulet Expands Omnipod 5 to Four More International Markets

Business Wire last month

PODD
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes

ACTON, Mass., March 18, 2025--Insulet to present results from trial of direct transition from multiple daily injections to Omnipod 5 in adults and children with type 1 diabetes

Business Wire last month

PODD

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

(0ADR.L)

Insulet Appoints Ashley McEvoy President and CEO

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

This Insulin Pump Maker Expands Into New Territory And Its Stock Shows Relative Strength

Insulet (NasdaqGS:PODD) Launches Omnipod 5 In Canada As Shares Dip 7%

Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above

Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

Insulet Gains 62.9% in a Year: What's Driving the Stock?

Insulet (NasdaqGS:PODD) Completes US$450 Million Debt Financing; 7 Day Share Price Up 5%

PODD Stock Gains Following the Launch of Omnipod 5 in Australia

Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers

PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5

LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day

Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data

Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections

3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan

Insulet Announces Pricing of Senior Notes Due 2033

Insulet Corporation (PODD): Among the Best Diabetes Stocks to Buy According to Billionaires

Insulet Chief Technology Officer Mark Field leaves

Insulet Expands Omnipod® 5 to Four More International Markets

From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes